FDA Approves Rasonque (daraxonrasib) for Adults With Metastatic Pancreatic Cancer by Madaline Spencer| Published on: Sep 4, 2026 +++

FDA Approves Rasonque (daraxonrasib) for Adults With Metastatic Pancreatic Cancer by Madaline Spencer| Published on: Sep 4, 2026 The US Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib) for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. https://checkrare.com/fda-approves-rasonque-daraxonrasib-for-adults-with-metastatic-pancreatic-cancer/ New FDA Approvals for Rare Diseases: From Autoimmune Disorders to Pancreatic Cancer | The CheckRare Brief Ep 5 by CheckRare Staff| Published on: Sep 3, 2026 In this episode of The CheckRare Brief, we discuss four recent FDA approvals, including LISRAYA for dermatomyositis and Imaavy for warm autoimmune hemolytic anemia (wAIHA), Mimrylo for polycythemia vera (PV), and Rasonque for pancreatic cancer. We also examine the recent measles outbreak in Pennsylvania. https://checkrare.com/new-fda-approvals-for-rare-diseases-from-autoimmune-disorders-to-pancreatic-cancer-the-checkrare-brief-ep-5/ FDA Approves Rusfertide for Treatment of Adults With Polycythemia Vera by Madaline Spencer| Published on: Sep 3, 2026 https://checkrare.com/fda-approves-rusfertide-for-treatment-of-adults-with-polycythemia-vera/ The US Food and Drug Administration (FDA) has approved Mimrylo (rusfertide) for the treatment of adults with polycythemia vera (PV). PV is a condition characterized by an increased production of red blood cells. Affected people may also have excess white blood cells and platelets. The excess cell levels lead to thicker blood and increased risk for serious thrombotic events and stroke. PV occurs more frequently in men than it does in women. The condition has been associated with genetic changes in the JAK2 and TET2 genes.